EGFR Mutations were detected in 38.5% (218/566) adenocarcinoma cases, 4.3% (15/352) squamous cell carcinoma, 42.1% (8/19) adenosquamous carcinoma and 9.5% (4/42) large cell lung carcinoma. Here, EGFR is linked to adenosquamous carcinoma.